377 related articles for article (PubMed ID: 17878607)
1. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer.
Tsuchida K; Nakatani M; Uezumi A; Murakami T; Cui X
Endocr J; 2008 Mar; 55(1):11-21. PubMed ID: 17878607
[TBL] [Abstract][Full Text] [Related]
2. Bone morphogenetic proteins.
Chen D; Zhao M; Mundy GR
Growth Factors; 2004 Dec; 22(4):233-41. PubMed ID: 15621726
[TBL] [Abstract][Full Text] [Related]
3. Growth differentiation factor-9 signaling is mediated by the type I receptor, activin receptor-like kinase 5.
Mazerbourg S; Klein C; Roh J; Kaivo-Oja N; Mottershead DG; Korchynskyi O; Ritvos O; Hsueh AJ
Mol Endocrinol; 2004 Mar; 18(3):653-65. PubMed ID: 14684852
[TBL] [Abstract][Full Text] [Related]
4. Cripto is a noncompetitive activin antagonist that forms analogous signaling complexes with activin and nodal.
Kelber JA; Shani G; Booker EC; Vale WW; Gray PC
J Biol Chem; 2008 Feb; 283(8):4490-500. PubMed ID: 18089557
[TBL] [Abstract][Full Text] [Related]
5. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.
Inman GJ; Nicolás FJ; Callahan JF; Harling JD; Gaster LM; Reith AD; Laping NJ; Hill CS
Mol Pharmacol; 2002 Jul; 62(1):65-74. PubMed ID: 12065756
[TBL] [Abstract][Full Text] [Related]
6. Modulation of activin and BMP signaling.
Harrison CA; Wiater E; Gray PC; Greenwald J; Choe S; Vale W
Mol Cell Endocrinol; 2004 Oct; 225(1-2):19-24. PubMed ID: 15451563
[TBL] [Abstract][Full Text] [Related]
7. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
[TBL] [Abstract][Full Text] [Related]
8. Cell-type specific regulation of myostatin signaling.
Kemaladewi DU; de Gorter DJ; Aartsma-Rus A; van Ommen GJ; ten Dijke P; 't Hoen PA; Hoogaars WM
FASEB J; 2012 Apr; 26(4):1462-72. PubMed ID: 22202673
[TBL] [Abstract][Full Text] [Related]
9. The orphan receptor ALK7 and the Activin receptor ALK4 mediate signaling by Nodal proteins during vertebrate development.
Reissmann E; Jörnvall H; Blokzijl A; Andersson O; Chang C; Minchiotti G; Persico MG; Ibáñez CF; Brivanlou AH
Genes Dev; 2001 Aug; 15(15):2010-22. PubMed ID: 11485994
[TBL] [Abstract][Full Text] [Related]
10. Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators.
Souza TA; Chen X; Guo Y; Sava P; Zhang J; Hill JJ; Yaworsky PJ; Qiu Y
Mol Endocrinol; 2008 Dec; 22(12):2689-702. PubMed ID: 18927237
[TBL] [Abstract][Full Text] [Related]
11. Cripto forms a complex with activin and type II activin receptors and can block activin signaling.
Gray PC; Harrison CA; Vale W
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5193-8. PubMed ID: 12682303
[TBL] [Abstract][Full Text] [Related]
12. Activin receptor signaling: a potential therapeutic target for osteoporosis.
Lotinun S; Pearsall RS; Horne WC; Baron R
Curr Mol Pharmacol; 2012 Jun; 5(2):195-204. PubMed ID: 21787285
[TBL] [Abstract][Full Text] [Related]
13. Activin A/bone morphogenetic protein (BMP) chimeras exhibit BMP-like activity and antagonize activin and myostatin.
Korupolu RV; Muenster U; Read JD; Vale W; Fischer WH
J Biol Chem; 2008 Feb; 283(7):3782-90. PubMed ID: 18056265
[TBL] [Abstract][Full Text] [Related]
14. Competition between type I activin and BMP receptors for binding to ACVR2A regulates signaling to distinct Smad pathways.
Szilágyi SS; Amsalem-Zafran AR; Shapira KE; Ehrlich M; Henis YI
BMC Biol; 2022 Feb; 20(1):50. PubMed ID: 35177083
[TBL] [Abstract][Full Text] [Related]
15. Nodal signaling uses activin and transforming growth factor-beta receptor-regulated Smads.
Kumar A; Novoselov V; Celeste AJ; Wolfman NM; ten Dijke P; Kuehn MR
J Biol Chem; 2001 Jan; 276(1):656-61. PubMed ID: 11024047
[TBL] [Abstract][Full Text] [Related]
16. An activin mutant with disrupted ALK4 binding blocks signaling via type II receptors.
Harrison CA; Gray PC; Fischer WH; Donaldson C; Choe S; Vale W
J Biol Chem; 2004 Jul; 279(27):28036-44. PubMed ID: 15123686
[TBL] [Abstract][Full Text] [Related]
17. Engagement of activin and bone morphogenetic protein signaling pathway Smad proteins in the induction of inhibin B production in ovarian granulosa cells.
Bondestam J; Kaivo-oja N; Kallio J; Groome N; Hydén-Granskog C; Fujii M; Moustakas A; Jalanko A; ten Dijke P; Ritvos O
Mol Cell Endocrinol; 2002 Sep; 195(1-2):79-88. PubMed ID: 12354674
[TBL] [Abstract][Full Text] [Related]
18. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2.
Macías-Silva M; Hoodless PA; Tang SJ; Buchwald M; Wrana JL
J Biol Chem; 1998 Oct; 273(40):25628-36. PubMed ID: 9748228
[TBL] [Abstract][Full Text] [Related]
19. Activins as Dual Specificity TGF-β Family Molecules: SMAD-Activation via Activin- and BMP-Type 1 Receptors.
Olsen OE; Hella H; Elsaadi S; Jacobi C; Martinez-Hackert E; Holien T
Biomolecules; 2020 Mar; 10(4):. PubMed ID: 32235336
[TBL] [Abstract][Full Text] [Related]
20. Activin signaling as an emerging target for therapeutic interventions.
Tsuchida K; Nakatani M; Hitachi K; Uezumi A; Sunada Y; Ageta H; Inokuchi K
Cell Commun Signal; 2009 Jun; 7():15. PubMed ID: 19538713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
